Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $608000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 25.1% to $608000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, up 157.08% year-over-year, with the annual reading at $3.0 million for FY2025, 157.08% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $608000.0 at Cartesian Therapeutics, roughly flat from $606000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.2 million in Q1 2025, with the low at $176000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $374600.0, with a median of $322000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 48.99% in 2023, then surged 531.69% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $401000.0 in 2021, then plummeted by 39.9% to $241000.0 in 2022, then grew by 12.86% to $272000.0 in 2023, then soared by 78.68% to $486000.0 in 2024, then grew by 25.1% to $608000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $608000.0, $606000.0, and $589000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.